You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(601607.SH):鹽酸克林黴素膠囊通過仿製藥一致性評價
格隆匯 06-17 16:12

格隆匯6月17日丨上海醫藥(601607.SH)公佈,近日,上海醫藥集團股份有限公司控股子公司上海新亞藥業閔行有限公司(簡稱“新亞閔行”)收到國家藥品監督管理局頒發的關於鹽酸克林黴素膠囊(以下簡稱“該藥品”)的《藥品補充申請批准通知書》(通知書編號:2022B01897、2022B01898),該藥品通過仿製藥一致性評價。

鹽酸克林黴素膠囊主要適用於由敏感厭氧菌,鏈球菌、肺炎球菌和葡萄球菌等敏感菌株引起的嚴重感染,由Pharmacia&Upjohn Co.研發,最早於1970年在美國上市。2021年1月,新亞閔行就該藥品仿製藥一致性評價向國家藥監局提出申請並獲受理。截至公吿日,公司針對該藥品的一致性評價已投入研發費用約人民幣773.64萬元。

截至公吿日,中國境內該藥品的主要生產廠家包括廣州一品紅製藥有限公司、重慶藥友製藥有限責任公司、四川科倫藥業股份有限公司、宜昌人福藥業有限責任公司等。

IQVIA數據庫顯示,2021年鹽酸克林黴素膠囊劑醫院採購金額為人民幣6.8689億元。2021年,新亞閔行的該藥品未進行銷售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account